Harvesting and concentration of human influenza a virus produced in serum-free mammalian cell culture for the production of vaccines

Biotechnology and Bioengineering

Volumn 97, Issue 1, 2007, Pages 73-85

  Kalbfuss, Bernd ^a   Genzel, Yvonne ^a   Wolff, Michael ^a   Zimmermann, Anke ^a   Morenweiser, Robert ^a,b   Reichl, Udo ^a,b  

^a MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Cell culture derived; Cross flow ultrafiltration; Downstream processing; Human influenza A virus; Serum free; Vaccine

Indexed keywords

DNA; DYNAMIC LIGHT SCATTERING; MAMMALS; TURBIDITY; ULTRAFILTRATION; VACCINES; VIRUSES;

CHEMICAL INACTIVATION; CROSS-FLOW ULTRAFILTRATION; DOWNSTREAM PROCESSING; GEL ELECTROPHORESIS; HUMAN INFLUENZA A VIRUS;

CELL CULTURE;

DNA; PROPIOLACTONE; PROTEIN; VACCINE;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL STRAIN; CONTROLLED STUDY; CROSSFLOW FILTRATION; CULTURE MEDIUM; HEMAGGLUTINATION; HOLLOW FIBER; INFLUENZA VIRUS A; LIGHT SCATTERING; MICROFILTRATION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; SHEAR RATE; SUPERNATANT; TURBIDITY; ULTRAFILTRATION; VACCINE PRODUCTION; VIRUS INACTIVATION;

ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; CULTURE MEDIA, SERUM-FREE; DOGS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; KIDNEY; VIRUS CULTIVATION;

INFLUENZA A VIRUS; MAMMALIA;

EID: 34247518571     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21139     Document Type: Article

References (30)

1. Braas G, Searle PF, Slater NKH, Lyddiatt A. 1996. Strategies for the isolation an purification of retroviral vectors for gene therapy. Bioseparation 6:211-228.
2. Bresler S, Kolikov V, Katushkina N, Molodkin V, Friedman E, Zheleznova H, Malafeieva L, Peradze T, Beljakov V, Ivanov K. 1975. Immunogenicity of inactivated influenza vaccine, purified by adsorption chromatography on porous glass. Med Biol 53:456-461.
3. Budowsky EI, Zalesskaya MA. 1991a. Principles of selective inactivation of viral genome. V. Rational selection of conditions for inactivation of the viral suspension infectivity to a given extent by the action of β-propiolactone. Vaccine 9:319-325.
4. Budowsky EI, Friedman EA, Zheleznova NV, Noskov FS. 1991b. Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of β-propiolactone. Vaccine 9:398-402.
5. Coulson JM, Richardson JF. 1991. Chemical engineering (Volume 2), Chapter 20: Membrane separation processes. Oxford: Butterworth-Heinemann.
6. Coulson JM, Richardson JF. 1997. Chemical engineering (Volume 1), Chapter 3: Flow in pipes and channels. Oxford: Butterworth-Heinemann.
7. Cruz PE, Peixoto CC, Devos K, Moreira JL, Saman E, Carrondo MJT. 1999. Characterization and downstream processing of HIV-1 core and virus-like particles produced in serum-free medium. Enzyme Microb Technol 26:61-70.
8. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. 1997. Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis). Cytometry 27:1-20.
9. Draper NR, Smith H. 1998. Applied regression analysis. New York: John Wiley & Sons.
10. Frazatti-Gallina NM, Mourao-Fuches RM, Paoli RL, Silva MLN, Miyaki C, Valentini EJG, Raw I, Higashi HG. 2004. Vero-cell rabies vaccine produced using serum-free medium. Vaccine 23:511-517.
11. Gerdil C. 2003. The annual production cycle for influenza vaccine. Vaccine 21:1776-1779.
12. Kistner O, Barret PN, Mundt W, Reiter M, Schober-Bendixen ??, Dorner F. 1998. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16:960-968.
13. Knipe DM, Howley PM. 2001. Fields virology, Chapter 46: Orthomyxoviridae. Philadelphia: Lippincott Williams & Wilkins.
14. Laemmli UK. 1970. Cleavage of structural proteins during assembly of head of bacteriophage-T4. Nature 227:680-685.
15. Mahy BWJ, Kangro HO. 1996. Virology methods manual. London: Academic Press. p 41-43.
16. Maranga L, Rueda P, Antonis AFG, Vela C, Langeveld JPM, Casal JI, Carrondo MJT. 2002. Large scale production and downstream processing of a recombinant porcine and parvovirus vaccine. Appl Microbiol Biotechnol 59:45-50.
17. Miller HK, Schlesinger RW. 1955. Differentiation and purification of influenza viruses by adsorption on aluminum phosphate. J Immunol 75:155-160.
18. Morenweiser R. 2005. Downstream processing of viral vectors and vaccines. Gene Ther 12:103-110.
19. Nayak DP, Hui EKW, Barman S. 2004. Assembly and budding of influenza virus. Virus Res 106:147-165.
20. Nayak DP, Lehmann S, Reichl U. 2005. Downstream processing of MDCK cell-derived equine influenza virus. J Chromatogr B 823:75-81.
21. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. 2001. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19:2716-2721.
22. Paul RW, Morris D, Hess BW, Dunn J, Overell RW. 1993. Increased viral titer through concentration of viral harvests from retroviral packaging lines. Hum Gene Ther 4:609-615.
23. Rabilloud T, Strub JM, Luche S, Dorsselaer A, Lunardi J. 2001. Comparison between Sypro Ruby and ruthenium II tris (bathophenanthroline disulfonate) as fluorescent stains for protein detection in gels. Proteomics 1:699-704.
24. Reichl U. 2000. ISCOM vaccines - antigen production and downstream processing. Proceedings of the 4th International Congress on Biochemical Engineering. Stuttgart: Fraunhofer IRB Verlag. p 314-318.
25. Reimer CB, Baker RS, van Frank RM, Newlin TE, Cline GB, Anderson NG. 1967. Purification of large quantities of influenza virus by density gradient centrifugation. J Virol 1:1207-1216.
26. Tree JA, Richardson C, Fooks AR, Clegg C, Looby D. 2001. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19:3444-3450.
27. Voeten JTM, Brands R, Palache AM, van Scharrenburg GJM, Rimmelzwaan GF, Osterhaus ADME, Claas ECJ. 1999. Characterization of high-growth reassortant influenza A viruses generated in MDCK cells cultured in serum-free medium. Vaccine 17:1942-1950.
28. Wessel D, Flügge UI. 1984. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 138:141-143.
29. Wickramasinghe SR, Kalbfuβ B, Zimmermann A, Thom V, Reichl U. 2005. Tangential flow microfiltration and ultrafiltration for human influenza A virus: Concentration and purification. 2004. Biotechnol Bioeng 92:199-208.
30. Wu D, Howell JA, Field RW. 1999. Critical flux measurement for model colloids. J Membr Sci 152:89-98.